Drug companion protocol
Ozempic
Active ingredient: Semaglutide
A GLP-1 receptor agonist primarily indicated for type 2 diabetes management, also prescribed off-label for weight management.
Quickstart Highlights
- Drug class
- GLP-1 receptor agonist
- Route
- Subcutaneous injection
- Schedule
- Weekly subcutaneous injection
- Evidence score
- 90
Quickstart highlights
- 💉Subcutaneous injection
- 🔬GLP-1 receptor agonist
- 🖊️Pre-filled autoinjector pen
- 📋Prescription required
How this works
Mechanism of action and pharmacokinetic profile from published data.
Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist. It mimics the gut hormone GLP-1 to increase glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite. In Ozempic, doses of 0.5–2 mg once weekly are used primarily to improve glycaemic control in type 2 diabetes. The glucose-dependent insulin effect means the risk of hypoglycaemia is low when semaglutide is used without other glucose-lowering agents.
Half-life
6.9 days
Tmax
2 days
Duration of action
7 days
- Time to peak (Tmax)
- 24–72 hours after subcutaneous injection.
- Clearance
- Degraded via proteolytic and fatty acid oxidation pathways; renal dose adjustment is not required for mild-to-moderate impairment.
- Elimination half-life
- Approximately 1 week (7 days), supporting once-weekly dosing.
- Bioavailability
- High systemic absorption after subcutaneous injection; ~89% albumin-bound, which extends the half-life.
Injection guide
Supplies, step-by-step technique, safety notes, and AU sharps disposal.
Dose escalation phases
Standard Ozempic escalation
| Phase | Dose | Frequency | Guidance |
|---|---|---|---|
| Weeks 1-4 Week 1-4 | 0.25 mg | once weekly | Initiation dose for tolerability. Escalate only under prescriber guidance. |
| Week 5 onward Week 5+ | 0.5 mg | once weekly | First therapeutic maintenance dose. Prescriber may increase after at least 4 weeks if additional glycaemic control is needed. |
| Optional 1 mg Week 9+ | 1 mg | once weekly | Dose increase for additional glycaemic control. Increase only if tolerated and prescribed. |
| Optional 2 mg Week 13+ | 2 mg | once weekly | Maximum labelled Ozempic dose in some regions. Use only when prescribed and available in the local product information. |
Supplies needed
- ◦Your prescribed Ozempic pen (correct strength) — Ozempic pens come in three strengths: 2 mg/1.5 mL (doses of 0.25 mg or 0.5 mg), 4 mg/3 mL (doses of 1 mg), and 8 mg/3 mL (doses of 2 mg). Confirm the pen strength matches your prescribed dose.
- ◦A new pen needle — NovoFine or equivalent, typically 4 mm × 32G. Always use a new needle for each injection.
- ◦Alcohol swab
- ◦Sharps disposal container
Step-by-step
- 1Wash your hands thoroughly
- 2Remove pen from fridge 30 minutes before use
Injecting room-temperature medicine is more comfortable and aids absorption.
- 3Check the pen and liquid
The solution should be clear and colourless. Check the expiry date. Never use a cloudy or discoloured pen.
- 4Attach a new needle and prime if it is a new pen
Attach the needle as described in the IFU. If this is a new pen or the first use after a break, do a flow check (prime): dial to the flow check symbol, point the pen upward, and press the button until a drop appears at the needle tip.
- 5Dial your prescribed dose
Turn the dose selector until the prescribed dose appears in the dose window. If you dial past your dose, you can turn back.
- 6Choose and clean your injection site
Abdomen (5 cm from navel), upper thigh, or upper arm. Wipe with an alcohol swab and let dry.
- 7Inject
Hold the pen at 90° to the skin. Press firmly and press the injection button all the way. Hold for 6 seconds until the dose counter returns to 0.
- 8Remove needle and dispose immediately
Recap using one-hand scoop, unscrew, drop directly into sharps container.
- 9Replace the pen cap and return to fridge
The pen can be used until all doses are delivered or the expiry date, whichever comes first.
Important notes
- !Never inject into a vein or muscle
- !Never share your pen
- !Rotate injection sites every week
- !Do not inject into scar tissue, bruises, or broken skin
- !If you miss a dose by more than 5 days, skip and resume on your regular day
- !Tell all healthcare providers you are using Ozempic
Gastric emptying is slowed — relevant for fasting before procedures and for absorption of oral medicines.
Sharps disposal
- ◦Sharps container — do not place loose needles in household bins
- ◦NestSafe mail-back (Australia) — free from participating pharmacies
- ◦EnviroSafe mail-back (Australia) — available from pharmacies
- ◦Community pharmacy drop-off — ask your dispensing pharmacy
Your journey
Where you are in a typical protocol, and what one dose cycle looks like. Educational — your prescriber tailors the plan to you.
Protocol timeline
Starter phase
Weeks 1–40.25 mgevery 7dWhat to expect: Body is adjusting to the medication, Mild nausea or digestive changes are common and usually temporary, Appetite may begin to reduce slightly, Blood glucose levels may begin to improve gradually
Focus on: Establish a consistent injection day and time, Eat smaller, lower-fat meals to minimise nausea, Stay well hydrated, Begin logging symptoms and blood glucose if advised by your prescriber
Common adjustments: No dose change expected during this phase — this dose is for tolerability, not full glycaemic effect, Prescriber may advise on injection technique and site rotation
First escalation
Weeks 5–80.5 mgevery 7dWhat to expect: Nausea may return or temporarily increase as dose rises, Appetite suppression typically becomes more noticeable, Blood glucose improvements may become more pronounced, Most people tolerate this dose well after the first 1–2 weeks
Focus on: Continue small, frequent, low-fat meals, Monitor for constipation and increase fluid and fibre intake proactively, Note any injection site reactions, Continue blood glucose monitoring as directed by your prescriber
Common adjustments: Prescriber may delay escalation if GI side effects are not well controlled, Constipation management strategies may be introduced
Therapeutic maintenance
Weeks 9+1 mgevery 7dWhat to expect: Sustained appetite suppression and improved glycaemic control expected, GI side effects typically ease after weeks 2–4 at this dose, Prescriber may consider further escalation to 2 mg based on individual response and tolerability, Weight changes may become more consistent
Focus on: Maintain consistent injection day each week, Focus on sustainable eating habits that work alongside reduced appetite, Keep all scheduled prescriber and pathology appointments, Report any new or worsening symptoms promptly
Common adjustments: Prescriber may escalate to 2 mg after at least 4 weeks on 1 mg if further glycaemic benefit is needed, Regular HbA1c and weight monitoring, Ongoing review of concomitant diabetes medications to manage hypoglycaemia risk
One dose cycle at a glance
Population typicals, in hours from your dose — individual experience varies.
Onset
24 h
Peak effect
24–72 h
Appetite effect
12–168 h
Nausea risk
6–72 h
Constipation risk
24–168 h
Coverage fades after
168 h
Semaglutide has a half-life of approximately 7 days, supporting once-weekly dosing. tmax is 24–72 hours post-injection. Nausea risk is highest in the first 24–72 hours after each dose and is more pronounced during dose escalation weeks. Appetite suppression and gastric-emptying effects persist across the full weekly interval. Constipation risk is spread across the entire week due to slowed gastrointestinal motility.
Clinical Benefits & Side Effects
Observed outcomes, adverse effects, and lifecycle considerations from published trial data.
Benefits
Starting Ozempic
Ozempic begins at 0.25 mg weekly for four weeks, then escalates to 0.5 mg. The starting dose is a tolerability step, not a therapeutic dose — blood sugar improvement and appetite change are more noticeable from 0.5 mg onward.
First injection — taking the first step
You've taken your first dose, and that's a big deal. Most people feel little to nothing this week, though some notice mild nausea, a reduced appetite, or loose stools — especially in the day or two after the injection. Go gently, eat smaller meals, and don't expect dramatic changes just yet.
Finding your injection routine
Your second injection is a chance to settle into a routine — same day, same time, same spot. Nausea, if it appeared last week, may still be present and can feel a little stronger for some people. Eating slowly and choosing plain, easy-to-digest foods can really help right now.
Side effects may peak — stay the course
Weeks 2–4 are often the toughest for nausea and digestive discomfort, as your body is still adjusting to the medication. You might notice some fatigue or a reduced desire to eat large meals. This is normal — it doesn't mean the medication isn't working, it means your body is responding.
One month in — body beginning to adjust
By the end of week four, many people notice the side effects beginning to ease a little. You're nearing the end of your starting dose phase, and your prescriber may soon discuss a dose increase. Don't be discouraged if the scale hasn't moved much — your body is doing a lot of internal adjusting.
Dose may increase — appetite shifts ahead
If your prescriber has increased your dose, week five can feel like a reset — some of the nausea you thought had passed might return briefly. This is very common with dose escalation. On the positive side, appetite suppression often becomes noticeably stronger around this time.
Appetite suppression becoming more noticeable
Many people report that food 'noise' — constant thoughts about eating — begins to quieten around this point. You may find yourself stopping mid-meal because you genuinely feel full. This is the medication working as intended, but be mindful to still eat enough nourishing food each day.
Learning to listen to your hunger cues
With appetite suppression more consistent, this is a great week to practise tuning in to true hunger versus habit-based eating. Some people also notice cravings for sweet or fatty foods reducing. Digestive side effects for most people are more manageable now than in the early weeks.
Side effects
Reported
- Pause solid food briefly, sip fluids, and restart bland foods once settled; do not escalate dose while vomiting persists.Seek help: Seek urgent advice for repeated vomiting, dehydration, or inability to keep fluids down.
3.0% vs 1.8% placebo — rapid glucose improvement may unmask pre-existing changes; discuss with your ophthalmologist
Common
- Prioritise fluids and electrolytes; avoid alcohol, greasy meals, and very high-sugar drinks until symptoms settle.Seek help: Seek help if diarrhoea is severe, bloody, accompanied by fever, or causes dehydration.
Generally mild and transient
- Rotate sites, let alcohol dry before injecting, and avoid bruised, scarred, or hardened skin.Seek help: Seek advice for spreading redness, warmth, pus, fever, or severe pain.
Reported
- Increase fluids, fibre-rich foods, and gentle movement; consider pharmacist advice for a short-term stool softener if needed.Seek help: Contact a clinician for severe abdominal pain, no bowel movement for several days, or vomiting with constipation.
Higher risk when combined with insulin or sulfonylureas
Common; most frequent during dose escalation
- Eat smaller, slower meals; choose bland lower-fat foods during escalation; avoid lying down soon after eating.Seek help: Contact your prescriber if nausea is severe, persistent, or prevents eating and drinking.
Lifecycle factors
Know the symptoms of low blood sugar if using other diabetes medicines
On its own, semaglutide rarely causes hypoglycaemia because its insulin-stimulating effect is glucose-dependent. However, if you are also using insulin or sulfonylureas, hypoglycaemia is a real risk. Know the signs: shakiness, sweating, confusion, rapid heartbeat.
Diabetic eye screening
Rapid improvement in blood sugar can occasionally cause transient worsening of diabetic eye changes. Attend your scheduled retinal screenings and let your ophthalmologist know you have started Ozempic.
Inform any medical or dental team
Delayed gastric emptying affects the timing and preparation for procedures requiring fasting or nil-by-mouth instructions. Tell every medical professional you see that you are on semaglutide.
Keep a symptom log to share with your prescriber
Tracking how you feel each week gives your prescriber genuinely useful information and helps them support you better. **Note down any side effects, their timing relative to your injection, and their severity** — even a simple 1–10 rating in your phone's notes app is helpful. This also helps you notice patterns, like realising nausea is worst on day two post-injection, which can inform when you choose to eat or plan activities.
Talk to your pharmacist — they're a great resource
Your pharmacist is an accessible and knowledgeable member of your care team, not just the person who hands you the medication. **They can answer questions about storage, injection technique, side effect management, and interactions with other medications**, often without needing an appointment. Don't hesitate to call or pop in between prescriber visits — that's exactly what they're there for.
Important note
This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment. All information presented is based on published clinical trial data. Always follow your prescriber's instructions.
Nutrition & practical guidance
Food, hydration, and adherence tips compiled from trial data and clinical companion content.
Food and hydration
✅ Prefer
⚠️ Limit
Adherence tips
Rotate your injection sites consistently
Semaglutide is injected subcutaneously — into the fatty layer just under the skin — in the abdomen, outer thigh, or upper arm. **Rotate your injection site each week** to prevent skin irritation or lumps forming (lipohypertrophy). Keep a simple note on your phone or a sticky note on your pen to track where you injected last. Follow your prescriber's instructions on technique if you're unsure.
Let your pen reach room temperature before injecting
Injecting cold medication straight from the fridge can increase discomfort and stinging at the injection site. **Take your pen out of the fridge 15–30 minutes before your injection** and let it come to room temperature. Store unused pens in the refrigerator (between 2°C and 8°C) and never freeze them.
Inject on the same day each week
Keeping a consistent injection schedule prevents accidental double-dosing or long gaps. A gap of more than 14 days between doses requires restarting the escalation protocol — contact your prescriber if that happens.
Choose a weekly injection day that works for your life
Pick a day of the week you can be consistent with — many people choose a day when they're home and relaxed, such as a Sunday morning. **Nausea tends to peak in the 24–48 hours after your injection**, so some people prefer to inject on a Friday night so the worst of it falls over the weekend. Set a phone reminder so you never have to think about whether you've done it.
Prioritise protein at every meal
When your appetite is suppressed, it's easy to under-eat — and when you eat less, protein is the most important thing to prioritise to protect your muscle mass. **Aim for a palm-sized serving of protein** (chicken, fish, eggs, legumes, Greek yoghurt) at every meal. Even on days when nausea is limiting what you can eat, a small protein-rich snack like a boiled egg or some cottage cheese can help.
Consistent carbohydrate distribution helps
Spreading carbohydrate intake evenly across meals, rather than loading at one meal, produces more stable glucose levels and can reduce post-meal nausea.
Eat smaller meals more frequently
Semaglutide slows how quickly your stomach empties, which means large meals can sit heavily and trigger nausea or reflux. **Try eating 4–5 smaller meals or snacks across the day** rather than 2–3 large ones. Stop eating when you feel *comfortably* satisfied — not stuffed — and eat slowly to give your body time to signal fullness.
Sip water consistently throughout the day
Dehydration can make nausea significantly worse, and it's easy to forget to drink when you're not feeling hungry or thirsty. **Keep a 600 mL water bottle visible** on your desk or bench and aim to refill it at least three times a day. Sipping steadily is far more effective than trying to drink large amounts in one go, which can also trigger nausea.
Try ginger tea when nausea strikes
Ginger has well-supported properties for easing nausea and is a practical, low-effort option. **Brew a cup of ginger herbal tea or add a few thin slices of fresh ginger to hot water** after meals or when you're feeling unsettled. Peppermint tea is another good option if ginger isn't your preference. Avoid carbonated drinks when you're feeling nauseous, as they can worsen bloating.
Measure progress beyond the scale
The number on the scale is just one small part of the picture. **Keep a simple weekly journal** noting your energy levels, how your clothes feel, your mood, sleep quality, and how you're coping with meals. Many of the most meaningful early changes — reduced food cravings, steadier energy, better blood sugar patterns — won't show up on the scale at all. Celebrate those wins too.
Be patient with the early weeks — they are the hardest
Weeks one to four are genuinely difficult for many people, and it's completely normal to question whether it's worth it when you're feeling nauseous and not yet seeing results. **The side effects almost always ease significantly after the first month** as your body adjusts. If you're struggling, reach out to your prescriber — there are practical strategies that can help, and you don't have to just push through alone.
Start with gentle movement — walking is enough
You don't need to overhaul your exercise routine straight away. In the early weeks, **a 20–30 minute walk a few times a week** is genuinely enough to support your health and boost your mood. As nausea and fatigue ease (usually from weeks 5–8), you can gradually increase intensity. Pushing too hard too soon can worsen fatigue and make the adjustment period harder.
Add resistance training to protect muscle
When losing weight, the body can lose muscle alongside fat — resistance training is the most effective way to minimise this. **Aim for 2 sessions of resistance exercise per week**, even if it's just bodyweight exercises at home (squats, push-ups, lunges). If you're new to this, a single session with a qualified exercise physiologist can give you a safe, personalised starting point.
Protect your sleep — it supports everything else
Poor sleep increases hunger hormones (particularly ghrelin) and can work against the appetite-regulating effects of the medication. **Aim for 7–9 hours of quality sleep** by keeping a consistent bedtime, reducing screen exposure in the hour before bed, and keeping your bedroom cool and dark. If nausea is disrupting your sleep, try sleeping with your head slightly elevated.
Dispose of used needles safely
Used sharps must be disposed of safely and responsibly — **never place them in household recycling or general rubbish bins**. In Australia, you can collect used needles in an approved sharps container and drop them off at your local pharmacy, council facility, or approved sharps disposal bin free of charge. Ask your pharmacist for a sharps container when you collect your prescription.
Daily companion
Practical playbooks for managing symptoms, eating around side effects, tracking what matters, and reporting back to your clinician.
Symptom playbooks
Nausea
Minimal or no nausea
Nutrition: Continue eating regular, balanced meals, Keep portions moderate — avoid very large meals, Eat slowly and chew thoroughly
Hydration: Aim for at least 2 L of water or non-caffeinated fluids daily, Sip fluids steadily throughout the day
Mild nausea
Nutrition: Eat smaller, more frequent meals (every 3–4 hours), Choose bland, low-fat foods — plain crackers, toast, rice, banana, boiled potato, Avoid eating large volumes in a single sitting, Eat at a relaxed pace; sit upright for at least 30 minutes after eating, Ginger-based foods or tea may help settle the stomach
Hydration: Sip fluids steadily — avoid large volumes at once, Try cold or room-temperature still water, Clear broths or diluted fruit juice can help maintain intake if plain water is unappealing
Avoid: High-fat or fried foods, Spicy or strongly flavoured meals, Alcohol, Eating lying down or immediately before bed, Carbonated drinks in large quantities
Moderate nausea
Nutrition: Prioritise very small, bland meals or snacks — even a few bites is better than nothing, Dry foods (plain crackers, dry toast) often tolerated best, Avoid skipping meals entirely if possible — an empty stomach can worsen nausea, Cold foods may be better tolerated than hot, strongly aromatic dishes
Hydration: Sip 1–2 tablespoons of fluid every 10–15 minutes if larger amounts trigger nausea, Oral rehydration solutions can help if fluid intake is reduced, Avoid very sweet or sugary drinks
Avoid: All high-fat, fried, or spicy foods, Strong food odours where possible, Alcohol and caffeine, Lying flat immediately after eating
⚠ If nausea at this level persists for more than 48 hours or is preventing adequate food and fluid intake, contact your prescriber. They may review your dose timing or escalation schedule.
Severe nausea or vomiting
Nutrition: Focus solely on keeping small amounts of bland food down if possible, Ice chips or frozen fruit pieces may help if solid food is not tolerated
Hydration: Maintaining hydration is the priority — sip fluids frequently in very small amounts, Oral rehydration solutions are preferred if vomiting is occurring, If you cannot keep fluids down for more than 24 hours, seek medical attention
Avoid: All solid foods until vomiting is under control, Alcohol, Caffeine
⚠ Seek urgent medical attention if you are unable to keep fluids down for more than 24 hours, show signs of dehydration (dizziness, dark urine, rapid heartbeat), or have severe abdominal pain alongside vomiting. Contact your prescriber before your next scheduled dose.
Constipation
Minimal or no constipation
Nutrition: Maintain adequate dietary fibre — vegetables, fruit, wholegrains, legumes, Continue regular meal timing
Hydration: Aim for at least 2 L of fluid daily, Adequate hydration supports healthy bowel function
Mild constipation
Nutrition: Gradually increase fibre intake — add extra vegetables, legumes, and wholegrains, Prunes, pear, kiwi fruit, and flaxseed may support bowel regularity, Avoid drastic sudden increases in fibre which may worsen bloating
Hydration: Increase fluid intake — aim for 2–2.5 L daily, Warm fluids in the morning (warm water with lemon) may help stimulate bowel activity
Avoid: Low-fibre processed foods, Dehydrating drinks (excessive alcohol, large amounts of caffeine)
Moderate constipation
Nutrition: Focus on fibre-rich foods at every meal, Psyllium husk (e.g. Metamucil) added to water or food may assist — discuss with your prescriber or pharmacist, Maintain regular meal times to support gut rhythm
Hydration: Prioritise fluid intake — at least 2.5 L daily, Fibre supplements require adequate fluid to be effective
Avoid: White bread, white rice, and other very low-fibre refined foods, Cheese and high-fat dairy in large quantities, Insufficient fluid intake alongside fibre increases
⚠ If constipation is uncomfortable or has not improved after 3–5 days of dietary measures, contact your prescriber or pharmacist. They may recommend an appropriate laxative. Do not use stimulant laxatives without professional guidance.
Severe constipation or no bowel movement for 5+ days
Nutrition: Continue high-fibre foods and fluids, Avoid adding more fibre without adequate fluid — this can worsen impaction
Hydration: Increase fluid intake to 2.5–3 L daily if tolerated, Warm fluids may help stimulate gut motility
Avoid: Any foods that further slow digestion — fatty, low-fibre, processed foods
⚠ Contact your prescriber or seek medical attention if you have not had a bowel movement for 5 or more days, or if you experience severe abdominal pain, bloating, or nausea alongside constipation. These may require assessment.
Low appetite
Good appetite
Nutrition: Continue balanced, regular meals, No specific changes needed
Hydration: Maintain at least 2 L of fluid daily
Reduced appetite
Nutrition: Eat smaller meals more frequently — prioritise nutrient-dense foods over large volumes, Include protein at each eating occasion to support muscle maintenance (e.g. eggs, legumes, lean meat, Greek yoghurt), Avoid letting yourself go too long without eating — small snacks help maintain energy and blood glucose stability, Smoothies or nourishing soups can be easier to consume when solid food feels unappealing
Hydration: Separate fluids from meals to avoid early fullness reducing food intake, Aim for at least 2 L of fluids daily
Avoid: Skipping meals entirely for extended periods, Filling up on low-nutrient foods or sugary drinks that crowd out more nourishing options
Very low appetite — nutritional intake at risk
Nutrition: Focus on calorie- and protein-dense foods in small amounts — nut butters, avocado, full-fat dairy, eggs, Set gentle meal reminders — do not rely on hunger cues alone, Consider fortified nutritional supplements (e.g. Sustagen, Ensure) if solid food intake is very limited — discuss with your prescriber or a dietitian, A referral to a dietitian is strongly recommended if this persists beyond 2–3 weeks
Hydration: Keep fluids going even when food intake is very low, Nutritious drinks (e.g. milk-based smoothies) can contribute both hydration and kilojoules
Avoid: Extended periods (more than 1–2 days) with very minimal food intake without professional guidance, Relying solely on liquids for nutrition without professional assessment
⚠ If your appetite is severely reduced for more than 3–5 consecutive days, or if you are losing weight rapidly or feeling very weak, contact your prescriber. Sustained inadequate nutrition may require a dose review or dietitian support.
Food guidance by situation
Prefer: Plain crackers or dry toast, Boiled or steamed plain rice, Banana or plain boiled potato, Ginger tea or ginger-based foods, Cold or room-temperature foods with mild aroma
Limit: Dairy in large amounts, Carbonated drinks, Very sweet foods and drinks
Avoid: High-fat or fried foods, Spicy or strongly flavoured meals, Alcohol, Large meal portions, Eating immediately before lying down
Semaglutide slows gastric emptying; high-fat and large meals remain in the stomach longer, significantly increasing nausea risk during the peak absorption window (24–72 hours post-dose).
Prefer: High-fibre vegetables (broccoli, carrots, peas, leafy greens), Fruit with skin (pear, apple, kiwi fruit), Prunes or dried figs, Wholegrains (oats, wholegrain bread, brown rice), Legumes (lentils, chickpeas, kidney beans), Flaxseed or psyllium husk (with adequate fluid)
Limit: White bread, white rice, refined cereals, Processed snack foods, Cheese in large quantities
Avoid: Low-fibre, highly processed diets, Inadequate fluid intake alongside fibre-rich foods
Reduced gastrointestinal motility from GLP-1 receptor agonism increases constipation risk. Adequate fibre and fluid intake are the primary dietary countermeasures.
Prefer: Nutrient-dense, small-portion foods — eggs, nut butters, avocado, Greek yoghurt, Protein-rich options at each eating occasion, Smoothies or soups for easier calorie and nutrient delivery, Fortified nutritional drinks if solid food is poorly tolerated (with prescriber or dietitian guidance)
Limit: Low-nutrient, high-sugar snacks and drinks that displace nourishing foods
Avoid: Extended meal skipping without professional guidance
Appetite suppression is an expected pharmacological effect. Prioritising nutritional quality over quantity helps maintain adequate protein and micronutrient intake when overall food volume is reduced.
Prefer: Small, bland, low-fat meals on dose day and the following 1–2 days, Cold or lukewarm foods with minimal cooking aromas, Ginger tea or ginger-containing foods
Limit: Meal size — keep portions small, Fat content — choose lean proteins and low-fat options
Avoid: Large meals within 2 hours of injection, Fried, greasy, or very rich foods in the 24–72 hours after the dose, Alcohol around the time of dosing
The 24–72-hour post-dose window coincides with peak semaglutide plasma concentrations (tmax), when gastric emptying is most slowed and nausea risk is highest.
Prefer: Consistent, simple meal patterns — familiar, easily tolerated foods, Adequate protein to support satiety and muscle maintenance, Foods high in soluble fibre (oats, psyllium) to support bowel regularity
Limit: Dietary variety changes — avoid introducing many new foods simultaneously, Alcohol — may worsen nausea and interact with blood glucose management
Avoid: High-fat, fried, or spicy foods during the first week at each new dose level, Large portion sizes, Skipping meals, which may increase hypoglycaemia risk if other glucose-lowering agents are used concurrently
Each dose escalation re-introduces a period of heightened GI sensitivity. Dietary simplicity during transition weeks minimises nausea and GI discomfort while the body adjusts.
Prefer: Small, upright meals, Low-acid foods — oats, bananas, wholegrain bread, lean proteins, Non-carbonated, non-caffeinated beverages
Limit: Tomato-based sauces and citrus, Caffeinated drinks, Chocolate and peppermint
Avoid: Large meals, Lying down within 2–3 hours of eating, Alcohol, Carbonated drinks, Spicy and high-fat foods
Delayed gastric emptying from semaglutide can worsen gastro-oesophageal reflux symptoms. Standard reflux dietary precautions are particularly relevant for people on this medication.
What to track
Suggested check-in cadence: dose day plus 2.
How would you rate your nausea over the past 48 hours? (0 = none, 10 = worst imaginable)
scale 0 10
How would you rate your appetite today? (0 = no appetite at all, 10 = normal appetite)
scale 0 10
How much has constipation bothered you since your last dose? (0 = not at all, 10 = severely)
scale 0 10
How would you rate your energy levels today? (0 = exhausted, 10 = full energy)
scale 0 10
What was your most recent fasting blood glucose reading? (mmol/L) (mmol/L)
decimal
What is your weight today? (kg) (kg)
decimal
Approximately how much fluid did you drink yesterday? (litres) (L)
decimal
Did you notice any redness, swelling, or itching at the injection site?
boolean
Have you had any abdominal pain since your last dose? (0 = none, 10 = severe)
scale 0 10
Take this to your appointment
Medication context: GLP-1 receptor agonist
Key metrics: Current semaglutide dose (mg) and duration at current dose, Weekly weight trend (kg) — graphed over time, Fasting blood glucose readings (mmol/L) — weekly trend, HbA1c (from pathology — for prescriber review), Average nausea score (0–10) across reporting period, Average constipation score (0–10) across reporting period, Average appetite score (0–10) across reporting period, Average energy score (0–10) across reporting period, Fluid intake (L/day) — trend across reporting period, Injection site reaction flags — any reported, Abdominal pain flags — any score ≥ 7 reported, Red-flag symptom alerts triggered — list with dates
Relevant symptoms: Nausea, Vomiting, Constipation, Diarrhoea, Abdominal pain or discomfort, Reduced appetite, Reflux or heartburn, Fatigue or low energy, Injection site reactions (redness, swelling, itching), Dizziness or lightheadedness, Vision changes, Neck lump or voice changes, Signs of hypoglycaemia (shakiness, sweating, confusion)
Safety and interactions
Share this information with your prescriber for personalised care decisions.
Red-flag symptoms — seek urgent care
- Severe or persistent abdominal painEmergencySevere abdominal pain — particularly pain that radiates to your back, is accompanied by vomiting, or does not settle — requires immediate medical attention. This may be a sign of pancreatitis, a serious but rare side effect associated with GLP-1 receptor agonists. Call 000 or go to your nearest emergency department. Do not wait for your next scheduled appointment.
- Neck lump, difficulty swallowing, or hoarse voiceUrgent careA lump or swelling in your neck, difficulty swallowing, or a persistently hoarse voice can be early warning signs that require prompt medical assessment. Contact your prescriber urgently or attend an urgent care centre. GLP-1 receptor agonists carry a potential (though rare in humans) association with thyroid C-cell tumours observed in animal studies.
- Signs of hypoglycaemia (shakiness, sweating, confusion, rapid heartbeat, pale skin)Urgent careSemaglutide alone has a low risk of hypoglycaemia. However, if you are also taking insulin or a sulfonylurea, low blood glucose can occur. If you experience shakiness, sweating, confusion, rapid heartbeat, or feel faint, follow your prescriber's hypoglycaemia action plan. If symptoms are severe or do not improve promptly with glucose intake, call 000.
- Severe allergic reaction (hives, swelling of face/throat, difficulty breathing)EmergencySymptoms of a serious allergic reaction — including widespread hives or rash, swelling of the face, lips, tongue or throat, or difficulty breathing — require immediate emergency care. Call 000 immediately. Do not administer any further doses.
- Sudden worsening of visionUrgent careRapid changes in blood glucose can occasionally be associated with acute worsening of diabetic retinopathy, particularly early in treatment. If you notice a sudden change in your vision, contact your prescriber or ophthalmologist urgently. Do not delay assessment.
- Unable to keep fluids down for more than 24 hoursUrgent careIf you have been vomiting and cannot keep any fluids down for more than 24 hours, you are at risk of dehydration and electrolyte imbalance, which can be serious — particularly if you take other diabetes medications. Contact your prescriber promptly or attend an urgent care centre for assessment.
- Signs of kidney problems (significant reduction in urination, ankle/leg swelling)Contact prescriberDehydration caused by prolonged nausea, vomiting, or diarrhoea can rarely affect kidney function. If you notice a significant reduction in how much you are urinating, swelling in your ankles or legs, or feel unusually fatigued alongside digestive symptoms, contact your prescriber.
- Injection site reaction that spreads, blisters, or does not resolveContact prescriberMinor redness or mild discomfort at the injection site is common and usually resolves quickly. However, if the reaction spreads, involves blistering, significant swelling, warmth, or has not improved within a few days, contact your prescriber for review.
- Thyroid C-cell tumour warning. Do not use Ozempic with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
- Severe abdominal pain. Seek urgent medical advice for severe or persistent abdominal pain, especially with vomiting or pain radiating to the back.
- Thyroid C-cell tumours. Semaglutide has caused thyroid C-cell tumours in animal studies. It is unknown whether this applies to humans. Do not use Ozempic if you or a blood relative has had medullary thyroid carcinoma (MTC), or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Tell your prescriber straight away if you notice a lump or swelling in your neck, hoarseness, difficulty swallowing, or shortness of breath.
- Thyroid tumour risk. Semaglutide has caused thyroid C-cell tumours in animals. Tell your prescriber immediately if you notice a lump or swelling in your neck, hoarseness, difficulty swallowing, or shortness of breath. Do not use Ozempic if you or a family member has had medullary thyroid carcinoma (MTC) or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN2).
- Pancreatitis symptoms. Ozempic has been associated with acute pancreatitis. Seek urgent medical attention if you develop severe and persistent pain in your abdomen (stomach area) that may spread to your back, with or without vomiting. Your prescriber may need to discontinue treatment if pancreatitis is confirmed.
- Serious allergic reaction. Serious allergic reactions (anaphylaxis) and angioedema have been reported with semaglutide. Seek emergency medical attention immediately if you experience swelling of the face, lips, tongue or throat, difficulty breathing, rapid heartbeat, or a sudden drop in blood pressure.
- Diabetic retinopathy worsening. Rapid improvement in blood glucose control has been associated with temporary worsening of diabetic retinopathy, particularly in people with pre-existing retinopathy. Tell your prescriber straight away if you experience any sudden changes to your vision.
- Severe nausea, vomiting, or diarrhoea — dehydration risk. Persistent vomiting or diarrhoea that prevents you from keeping fluids down can lead to dehydration and may affect your kidney function. Contact your prescriber promptly if this occurs, particularly if you also take medicines for blood pressure or kidneys.
- Dehydration and kidney effects. Nausea, vomiting, and diarrhoea caused by Ozempic can lead to dehydration, which may worsen kidney function. Ensure you drink adequate fluids, and contact your prescriber if you are unable to keep fluids down or notice a significant decrease in urination.
Structured warnings
Thyroid C-cell tumour warning
Do not use Ozempic with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
Severe abdominal pain
Seek urgent medical advice for severe or persistent abdominal pain, especially with vomiting or pain radiating to the back.
Diabetic retinopathy monitoring
Rapid improvement in glucose can transiently worsen diabetic retinopathy. People with existing retinopathy need prescriber-led monitoring.
Thyroid C-cell tumours
Semaglutide has caused thyroid C-cell tumours in animal studies. It is unknown whether this applies to humans. Do not use Ozempic if you or a blood relative has had medullary thyroid carcinoma (MTC), or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Tell your prescriber straight away if you notice a lump or swelling in your neck, hoarseness, difficulty swallowing, or shortness of breath.
Thyroid tumour risk
Semaglutide has caused thyroid C-cell tumours in animals. Tell your prescriber immediately if you notice a lump or swelling in your neck, hoarseness, difficulty swallowing, or shortness of breath. Do not use Ozempic if you or a family member has had medullary thyroid carcinoma (MTC) or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN2).
Pancreatitis symptoms
Ozempic has been associated with acute pancreatitis. Seek urgent medical attention if you develop severe and persistent pain in your abdomen (stomach area) that may spread to your back, with or without vomiting. Your prescriber may need to discontinue treatment if pancreatitis is confirmed.
Serious allergic reaction
Serious allergic reactions (anaphylaxis) and angioedema have been reported with semaglutide. Seek emergency medical attention immediately if you experience swelling of the face, lips, tongue or throat, difficulty breathing, rapid heartbeat, or a sudden drop in blood pressure.
Diabetic retinopathy worsening
Rapid improvement in blood glucose control has been associated with temporary worsening of diabetic retinopathy, particularly in people with pre-existing retinopathy. Tell your prescriber straight away if you experience any sudden changes to your vision.
Severe nausea, vomiting, or diarrhoea — dehydration risk
Persistent vomiting or diarrhoea that prevents you from keeping fluids down can lead to dehydration and may affect your kidney function. Contact your prescriber promptly if this occurs, particularly if you also take medicines for blood pressure or kidneys.
Dehydration and kidney effects
Nausea, vomiting, and diarrhoea caused by Ozempic can lead to dehydration, which may worsen kidney function. Ensure you drink adequate fluids, and contact your prescriber if you are unable to keep fluids down or notice a significant decrease in urination.
Low blood glucose (hypoglycaemia) risk with other medicines
Ozempic alone has a low risk of causing low blood glucose. However, if you also take insulin or a sulfonylurea (e.g. glipizide, gliclazide), your risk of hypoglycaemia is higher. Talk to your prescriber about whether your other glucose-lowering medicines need to be adjusted.
Low blood sugar (hypoglycaemia) with combination therapy
When Ozempic is used alongside insulin or a sulfonylurea, the risk of hypoglycaemia (low blood sugar) increases. Symptoms include shakiness, sweating, dizziness, confusion, and rapid heartbeat. Your prescriber may adjust your other diabetes medicines when starting Ozempic.
Indication and approval status
Glycaemic control in adults with type 2 diabetes and cardiovascular risk reduction in selected adults with type 2 diabetes.
Adults with type 2 diabetes according to label criteria.
Treatment of adults with insufficiently controlled type 2 diabetes as an adjunct to diet and exercise.
Adults with type 2 diabetes according to product information.
Weight management use outside diabetes indication varies by jurisdiction and prescriber judgement.
Not the primary Ozempic label indication.
Who should not take this
Ozempic is a prescription medicine. Do not use if you have: • A personal or family history of medullary thyroid carcinoma (MTC) • Multiple endocrine neoplasia syndrome type 2 (MEN2) • A known allergy or hypersensitivity to semaglutide or any ingredient in the product Use with caution (discuss with your prescriber) if you have: • A history of pancreatitis • Diabetic retinopathy — discuss the risk of acute worsening during rapid glucose improvement • Severe kidney or liver disease • Active or recent eating disorder Not recommended during pregnancy or breastfeeding. Always disclose your full medical history to your prescriber.
Known interactions
- Insulin and insulin secretagogues (e.g. sulfonylureas)significant
Combination significantly increases hypoglycaemia risk. Prescribers typically reduce insulin or sulfonylurea doses when starting or escalating Ozempic.
- Oral contraceptivesmoderate
Gastric slowing may reduce the absorption of oral contraceptives, particularly around dose escalation. Discuss contraception options with your prescriber.
- Medicines with narrow therapeutic indexmoderate
Delayed gastric emptying may alter absorption of warfarin, some anti-epileptics, and ciclosporin. Additional monitoring may be warranted.
- Alcoholmoderate
Increases nausea and the risk of hypoglycaemia when combined with insulin or sulfonylureas.
Missed-dose guidance
If a weekly Ozempic dose is missed and it has been 5 days or less, take it as soon as possible.
Resume the regular weekly schedule after the missed dose is handled.
If more than 5 days have passed, skip the missed dose.
Do not take two doses close together; resume on the next scheduled day.
If you miss your weekly dose, administer it as soon as you remember — provided your next scheduled dose is at least 2 days (48 hours) away. If fewer than 2 days remain until your next scheduled dose, omit the missed dose and continue on your regular day.
After a missed dose, resume your normal once-weekly dosing schedule on your usual day. Do not administer two doses in the same week to make up for a missed one.
If you miss your weekly dose and your next scheduled dose is more than 2 days (48 hours) away, take the missed dose as soon as you remember — up to 5 days (120 hours) after the missed dose. If your next scheduled dose is within 2 days (48 hours), omit the missed dose and continue on your regular weekly schedule.
After resuming, continue on your usual day-of-the-week schedule. Do not take two doses in the same week.
When to seek help
Nausea that prevents normal eating or hydration, or persists beyond the escalation period.
Contact your prescriber; dose timing or escalation may need review.
Repeated vomiting, vomiting lasting more than 24 hours, or inability to keep fluids down.
Seek medical advice promptly; urgent care if dehydration symptoms occur.
Severe or persistent abdominal pain, especially with vomiting or pain radiating to the back.
Seek urgent assessment for pancreatitis or gallbladder disease.
Shaking, sweating, confusion, fainting, or low glucose readings when also using insulin or sulfonylureas.
Treat low glucose according to your diabetes plan and seek help if severe or not improving.
Side-effect timing windows
Population typicals from trial data — individual experience varies.
Nausea
Onset 1–24 h · Peak 24–72 h · Resolves ~14d
Most pronounced after the first dose and after each escalation step; usually settles within 1-2 weeks at a stable dose.
Vomiting
Onset 2–24 h · Peak 24–72 h · Resolves ~7d
Typically follows the same window as nausea; if persistent beyond 48h or unable to keep fluids down, contact prescriber.
Diarrhoea
Onset 4–48 h · Peak 24–96 h · Resolves ~7d
May alternate with constipation across the weekly cycle.
Constipation
Onset 24–96 h · Peak 48–168 h · Resolves ~14d
Driven by slowed gastric emptying; usually improves with hydration and fibre.
Injection-site reaction
Onset 0.5–4 h · Peak 1–12 h · Resolves ~2d
Includes localised redness, swelling, or itching at the injection site. Generally mild and self-limiting. Proper site rotation reduces recurrence.
Decreased appetite
Onset 1–24 h · Peak 24–72 h · Resolves —
A pharmacodynamic effect related to GLP-1 receptor agonism and central appetite suppression. May persist throughout treatment. Resolution days listed as null as appetite suppression is an ongoing effect during therapy.
Approved injection sites
Abdomen
Rotate weekly between abdomen, thigh and upper arm. Keep at least 2 cm from the navel and at least 2.5 cm from the previous site.
Avoid: Avoid skin that is bruised, tender, scarred or hardened.
Thigh
Front of the thigh, midway between hip and knee.
Avoid: Avoid the inner thigh.
Upper arm
Back of the upper arm; usually needs a helper to inject.
Avoid: Avoid the muscle - use the fatty layer just under the skin.
Structured storage
multi-dose pen
before first use
Refrigerate at 2-8 C
Keep capped and protected from light. Do not use if frozen, cloudy, discoloured, or particulate.
multi-dose pen
after first use
Below 30 C or refrigerated at 2-8 C
Use within 56 days after first use.
Remove the needle after each injection and replace the pen cap.
Storage and handling
Store the Ozempic pen in the refrigerator at 2–8°C (36–46°F) until first use. • After first use: keep below 30°C and use within 56 days (8 weeks). • Do not freeze — freezing damages the active molecule. • Keep the cap on between injections to protect from light. • Store away from children.
Research evidence
Published studies, labels, regulator pages, and curated protocol sources connected to this profile.
API source references
Ozempic prescribing information
Novo Nordisk. Ozempic (semaglutide) prescribing information.
Open source ↗Ozempic product information
Therapeutic Goods Administration product information for Ozempic.
Open source ↗SUSTAIN 6 trial
Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016.
Open source ↗Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT)
Human trial · 2023 · New England Journal of Medicine · n=17604 · Adults with overweight or obesity, established cardiovascular disease, without type 2 diabetes at baseline
17,604 adults with established cardiovascular disease were randomised to semaglutide 2.4 mg weekly or placebo over ~33 months. Semaglutide reduced the risk of major adverse cardiovascular events (MACE — cardiovascular death, non-fatal MI, or non-fatal stroke) by 20% versus placebo (HR 0.80, 95% CI 0.72–0.90).
Reported outcomes
- cardiovascular: 20% relative risk reduction in MACE versus placebo over ~33 months (SELECT trial — patients without diabetes). (Primary outcome)
Semaglutide versus Dulaglutide Once Weekly in Adults with Type 2 Diabetes (SUSTAIN 7)
Human trial · 2018 · The Lancet Diabetes & Endocrinology · n=1201 · Adults with type 2 diabetes uncontrolled on metformin
1,201 adults with type 2 diabetes on metformin were randomised to semaglutide 0.5 mg or 1 mg versus dulaglutide 0.75 mg or 1.5 mg weekly for 40 weeks. HbA1c reduction was significantly greater with semaglutide at matched doses, as was body-weight reduction. Adverse events were comparable.
DOI: 10.1016/S2213-8587(17)30423-X ↗Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6)
Human trial · 2016 · New England Journal of Medicine · n=3297 · Adults with type 2 diabetes and high cardiovascular risk
3,297 adults with type 2 diabetes and high cardiovascular risk were randomised to once-weekly subcutaneous semaglutide 0.5 mg or 1 mg, or placebo, for 104 weeks. MACE occurred in 6.6% of semaglutide participants versus 8.9% of placebo (HR 0.74, 95% CI 0.58–0.95), meeting the prespecified non-inferiority and superiority criteria.
Reported outcomes
- hba1c_reduction: HbA1c reductions of 1.1–1.4% across dose arms versus 0.4% with placebo at 104 weeks. (Secondary)
- weight_loss: Body-weight reduction of 3.6–6.0 kg versus 1.4 kg placebo depending on dose. (Secondary)
- cardiovascular: MACE occurred in 6.6% of semaglutide participants versus 8.9% of placebo over 104 weeks (HR 0.74), meeting non-inferiority and superiority criteria. (Primary outcome)
Reported dosage
- 1 mg · once weekly subcutaneous · 104 weeks — Higher dose arm in SUSTAIN-6.
- 0.5 mg · once weekly subcutaneous · 104 weeks — Lower dose arm in SUSTAIN-6; after initial 0.25 mg run-in.
Get the full companion experience in Viora
Week-by-week reminders, food and symptom tracking, and the complete companion guide in one place.
Available on iOS and Android.